Vivos Therapeutics Files S-1/A Update

TL;DR

Vivos Therapeutics (VVOS) filed an S-1/A showing $1.9M product revenue and $1.7M service revenue for 9 months ending Sep 30, 2024.

AI Summary

Vivos Therapeutics, Inc. filed an S-1/A on January 29, 2025, detailing its financial performance. For the nine months ended September 30, 2024, the company reported $1.9 million in product revenue and $1.7 million in service revenue. This filing provides an update on its business operations and financial standing.

Why It Matters

This filing provides investors with updated financial information for Vivos Therapeutics, Inc., crucial for assessing the company's performance and investment potential in the medical device sector.

Risk Assessment

Risk Level: medium — As an S-1/A filing, it indicates a company is seeking to raise capital or has recently gone public, which inherently carries higher risk than established public companies.

Key Numbers

• $1.9B — Product Revenue (For the nine months ended September 30, 2024)
• $1.7B — Service Revenue (For the nine months ended September 30, 2024)
• 20250129 — Filing Date (Date the S-1/A was submitted)

Key Players & Entities

• Vivos Therapeutics, Inc. (company) — Filer of the S-1/A
• 0001493152-25-004057 (filing_id) — Accession number for the filing
• 20250129 (date) — Filing date
• 333-284399 (filing_number) — SEC file number
• Littleton, CO (location) — Company's business and mailing address
• $1.9 million (dollar_amount) — Product revenue for the nine months ended September 30, 2024
• $1.7 million (dollar_amount) — Service revenue for the nine months ended September 30, 2024

FAQ

Key Financial Figures

• $0.0001 — 4,332 shares of Common Stock, par value $0.0001 per share ("Common Stock"), of Vivos Th
• $4.22 — Common Stock as reported on Nasdaq was $4.22 per share. We are an "emerging growth
• $149.6 billion — OSA has an annual societal cost of over $149.6 billion. According to the study " Global Preval

Filing Documents

• forms-1a.htm (S-1/A) — 3669KB
• ex23-1.htm (EX-23.1) — 3KB
• ex23-2.htm (EX-23.2) — 4KB
• forms-1_001.jpg (GRAPHIC) — 7KB
• ex23-1_001.jpg (GRAPHIC) — 4KB
• ex23-1_002.jpg (GRAPHIC) — 7KB
• 0001493152-25-004057.txt ( ) — 12563KB
• vvos-20240930.xsd (EX-101.SCH) — 59KB
• vvos-20240930_cal.xml (EX-101.CAL) — 86KB
• vvos-20240930_def.xml (EX-101.DEF) — 288KB
• vvos-20240930_lab.xml (EX-101.LAB) — 440KB
• vvos-20240930_pre.xml (EX-101.PRE) — 396KB
• forms-1a_htm.xml (XML) — 2341KB

Risk Factors

Risk Factors 16 Cautionary Note Regarding Forward-Looking Statements 36

Use of Proceeds

Use of Proceeds 38 Dividend Policy 38 Determination of Offering Price 38 Market for Common Equity and Related Stockholder Matters 38

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 38

Business

Business 55 Management 84

Executive Compensation

Executive Compensation 89 Certain Relationships and Related Party Transactions 101 Principal Stockholders 102

Description of Capital Stock

Description of Capital Stock 103 Selling Stockholders 110 Plan of Distribution 113 Legal Matters 114 Experts 114 Where You Can Find More Information 114 Index to Consolidated Financial Statements F-1 Please read this prospectus carefully. It describes our business, our financial condition and our results of operations. We have prepared this prospectus so that you will have the information necessary to make an informed investment decision. You should rely only on the information contained or incorporated by reference in this prospectus. We and the selling stockholders have not authorized anyone to provide you with any information or to make any representations about us, the securities being offered pursuant to this prospectus or any other matter discussed in this prospectus, other than the information and representations contained or incorporated by reference in this prospectus. If any other information or representation is given or made, such information or representation may not be relied upon as having been authorized by us. The information contained or incorporated by reference in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our Common Stock. Neither the delivery of this prospectus nor any distribution of securities in accordance with this prospectus shall, under any circumstances, imply that there has been no change in our affairs since the date of this prospectus. This prospectus will be updated and made available for delivery to the extent required by the federal securities laws. We are responsible for the disclosure in this prospectus. However, this prospectus includes industry data that we obtained from internal surveys, market research, publicly available information and industry publications. The market research, publicly available information and industry publications that we use generally state that the information contained therein has

View Full Filing

View this S-1/A filing on SEC EDGAR